Pontus Larsson

Pontus Larsson

Auto-generated profile, based on publicly available information

Pontus Larsson

Department of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University , Box 1432, BMC 751 44, Uppsala

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PFPaul Flicek
Paul Flicek
MAM. Ridwan Amode
M. Ridwan Amode
DBDaniel Barrell
Daniel Barrell
KBKathryn Beal
Kathryn Beal
SBSimon Brent
Simon Brent
SSStephen M. J. Searle
Stephen M. J. Searle
The Ensembl project (http://www.ensembl.org) provides genome resources for chordate genomes with a particular focus on human genome data as well as data for key model organisms such as mouse, rat and zebrafish. Five additional species were added in the last year including gibbon (Nomascus leucogenys) and Tasmanian devil (Sarcophilus harrisii) bringing the total number of supported species to 61 as of Ensembl release 64 (September 2011). Of these, 55 species appear on the main Ensembl website and six species are provided on the Ensembl preview site (Pre!Ensembl; http://pre.ensembl.org) with preliminary support. The past year has also seen improvements across the project.

2 November 2010 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
PFPaul Flicek
Paul Flicek
MAM. Ridwan Amode
M. Ridwan Amode
DBDaniel Barrell
Daniel Barrell
KBKathryn Beal
Kathryn Beal
SBSimon Brent
Simon Brent
SSStephen M. J. Searle
Stephen M. J. Searle
The Ensembl project ( http://www.ensembl.org ) seeks to enable genomic science by providing high quality, integrated annotation on chordate and selected eukaryotic genomes within a consistent and accessible infrastructure. All supported species include comprehensive, evidence-based gene annotations and a selected set of genomes includes additional data focused on variation, comparative, evolutionary, functional and regulatory annotation. The most advanced resources are provided for key species including human, mouse, rat and zebrafish reflecting the popularity and importance of these species in biomedical research. As of Ensembl release 59 (August 2010), 56 species are supported of which 5 have been added in the past year. Since our previous report, we have substantially improved the presentation and integration of both data of disease relevance and the regulatory state of different cell types.

24 October 2005 in Nucleic Acids Research
Verified
Journal Article
Open access
MKMarkus Kuhlmann
Markus Kuhlmann
BBBranimira E Borisova
Branimira E Borisova
MKMarkus Kaller
Markus Kaller
PLPontus Larsson
Pontus Larsson
DSDirk Stach
Dirk Stach
WNWolfgang Nellen
Wolfgang Nellen
We have identified a DNA methyltransferase of the Dnmt2 family in Dictyostelium that was denominated DnmA. Expression of the dnmA gene is downregulated during the developmental cycle. Overall DNA methylation in Dictyostelium is approximately 0.2% of the cytosine residues, which indicates its restriction to a limited set of genomic loci. Bisulfite sequencing of specific sites revealed that DnmA is responsible for methylation of mostly asymmetric C-residues in the retrotransposons DIRS-1 and Skipper. Disruption of the gene resulted in a loss of methylation and in increased transcription and mobilization of Skipper. Skipper transcription was also upregulated in strains that had genes encoding components of the RNA interference pathway disrupted. In contrast, DIRS-1 expression was not affected by a loss of DnmA but was strongly increased in strains that had the RNA-directed RNA polymerase gene rrpC disrupted. A large number of siRNAs were found that corresponded to the DIRS-1 sequence, suggesting concerted regulation of DIRS-1 expression by RNAi and DNA modification. No siRNAs corresponding to the standard Skipper element were found. The data show that DNA methylation plays a crucial role in epigenetic gene silencing in Dictyostelium but that different, partially overlapping mechanisms control transposon silencing.

15 April 2010 in Genome Medicine
Verified
Journal Article
Open access
PDF file
RDRaymond Dalgleish
Raymond Dalgleish
PFPaul Flicek
Paul Flicek
FCFiona Cunningham
Fiona Cunningham
AAAlex Astashyn
Alex Astashyn
RTRaymond E Tully
Raymond E Tully
DMDonna R Maglott
Donna R Maglott
As our knowledge of the complexity of gene architecture grows, and we increase our understanding of the subtleties of gene expression, the process of accurately describing disease-causing gene variants has become increasingly problematic. In part, this is due to current reference DNA sequence formats that do not fully meet present needs. Here we present the Locus Reference Genomic (LRG) sequence format, which has been designed for the specific purpose of gene variant reporting. The format builds on the successful National Center for Biotechnology Information (NCBI) RefSeqGene project and provides a single-file record containing a uniquely stable reference DNA sequence along with all relevant transcript and protein sequences essential to the description of gene variants. In principle, LRGs can be created for any organism, not just human. In addition, we recognize the need to respect legacy numbering systems for exons and amino acids and the LRG format takes account of these. We hope that widespread adoption of LRGs - which will be created and maintained by the NCBI and the European Bioinformatics Institute (EBI) - along with consistent use of the Human Genome Variation Society (HGVS)-approved variant nomenclature will reduce errors in the reporting of variants in the literature and improve communication about variants affecting human health. Further information can be found on the LRG web site: http://www.lrg-sequence.org.

26 November 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
JMJacqueline A. L. MacArthur
Jacqueline A. L. MacArthur
JMJoannella Morales
Joannella Morales
RTRay E. Tully
Ray E. Tully
AAAlex Astashyn
Alex Astashyn
LGLaurent Gil
Laurent Gil
FCFiona Cunningham
Fiona Cunningham
Locus Reference Genomic (LRG; http://www.lrg-sequence.org/) records contain internationally recognized stable reference sequences designed specifically for reporting clinically relevant sequence variants. Each LRG is contained within a single file consisting of a stable ‘fixed’ section and a regularly updated ‘updatable’ section. The fixed section contains stable genomic DNA sequence for a genomic region, essential transcripts and proteins for variant reporting and an exon numbering system. The updatable section contains mapping information, annotation of all transcripts and overlapping genes in the region and legacy exon and amino acid numbering systems. LRGs provide a stable framework that is vital for reporting variants, according to Human Genome Variation Society (HGVS) conventions, in genomic DNA, transcript or protein coordinates. To enable translation of information between LRG and genomic coordinates, LRGs include mapping to the human genome assembly. LRGs are compiled and maintained by the National Center for Biotechnology Information (NCBI) and European Bioinformatics Institute (EBI). LRG reference sequences are selected in collaboration with the diagnostic and research communities, locus-specific database curators and mutation consortia. Currently >700 LRGs have been created, of which >400 are publicly available. The aim is to create an LRG for every locus with clinical implications.

1 January 2014 in BMC Genomics
Verified
Journal Article
Open access
PDF file
HSHenrik Stranneheim
Henrik Stranneheim
MEMartin Engvall
Martin Engvall
KNKarin Naess
Karin Naess
NLNicole Lesko
Nicole Lesko
PLPontus Larsson
Pontus Larsson
AWAnna Wedell
Anna Wedell
Massively parallel DNA sequencing (MPS) has the potential to revolutionize diagnostics, in particular for monogenic disorders. Inborn errors of metabolism (IEM) constitute a large group of monogenic disorders with highly variable clinical presentation, often with acute, nonspecific initial symptoms. In many cases irreversible damage can be reduced by initiation of specific treatment, provided that a correct molecular diagnosis can be rapidly obtained. MPS thus has the potential to significantly improve both diagnostics and outcome for affected patients in this highly specialized area of medicine.